Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedJul 01, 2026
DataAggregated Company Financials
Companies9
  • 7D2.7%
  • 3M5.0%
  • 1Y31.7%
  • YTD9.4%

In the last week, the Pharma industry is up 2.7%, with Roche Holding leading the way, up 2.3%. This means that the industry has gained 32% over the past year. Earnings are forecast to grow by 11% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 01 Jul 2026CHF 577.1bCHF 122.9bCHF 25.1b36.8x23x4.7x
Fri, 29 May 2026CHF 561.3bCHF 121.2bCHF 24.8b39.4x22.6x4.6x
Sun, 26 Apr 2026CHF 546.0bCHF 121.3bCHF 25.1b37.5x21.7x4.5x
Tue, 24 Mar 2026CHF 529.6bCHF 121.3bCHF 25.2b35.9x21x4.4x
Thu, 19 Feb 2026CHF 610.3bCHF 119.5bCHF 24.3b37.3x25.1x5.1x
Sat, 17 Jan 2026CHF 591.2bCHF 121.6bCHF 21.6b36.9x27.4x4.9x
Mon, 15 Dec 2025CHF 543.3bCHF 121.1bCHF 21.5b33.2x25.2x4.5x
Wed, 12 Nov 2025CHF 511.7bCHF 121.3bCHF 21.6b33.5x23.7x4.2x
Fri, 10 Oct 2025CHF 520.3bCHF 120.9bCHF 21.1b33.9x24.7x4.3x
Sun, 07 Sep 2025CHF 497.6bCHF 120.3bCHF 20.9b31.4x23.8x4.1x
Tue, 05 Aug 2025CHF 457.9bCHF 120.8bCHF 20.9b23x21.9x3.8x
Thu, 03 Jul 2025CHF 453.1bCHF 116.9bCHF 18.8b25x24.1x3.9x
Sat, 31 May 2025CHF 445.5bCHF 119.0bCHF 19.3b25.5x23.1x3.7x
Mon, 28 Apr 2025CHF 426.6bCHF 118.1bCHF 18.5b25.2x23x3.6x
Wed, 26 Mar 2025CHF 473.9bCHF 121.7bCHF 19.2b29.4x24.7x3.9x
Fri, 21 Feb 2025CHF 477.4bCHF 122.4bCHF 19.1b23.1x25x3.9x
Sun, 19 Jan 2025CHF 439.9bCHF 120.0bCHF 21.5b18.3x20.5x3.7x
Tue, 17 Dec 2024CHF 424.7bCHF 118.6bCHF 21.2b18x20x3.6x
Thu, 14 Nov 2024CHF 437.7bCHF 118.1bCHF 21.2b18.7x20.7x3.7x
Sat, 12 Oct 2024CHF 457.6bCHF 115.3bCHF 19.4b21.7x23.6x4x
Mon, 09 Sep 2024CHF 459.3bCHF 114.4bCHF 19.2b22x23.9x4x
Wed, 07 Aug 2024CHF 440.2bCHF 114.9bCHF 19.4b22x22.7x3.8x
Fri, 05 Jul 2024CHF 431.9bCHF 116.5bCHF 19.8b34.2x21.8x3.7x
Sun, 02 Jun 2024CHF 412.6bCHF 116.7bCHF 19.8b41.9x20.8x3.5x
Tue, 30 Apr 2024CHF 393.8bCHF 113.4bCHF 19.9b38.3x19.7x3.5x
Thu, 28 Mar 2024CHF 387.8bCHF 112.1bCHF 19.4b37.9x20x3.5x
Sat, 24 Feb 2024CHF 390.6bCHF 110.4bCHF 19.7b24.8x19.8x3.5x
Mon, 22 Jan 2024CHF 413.6bCHF 120.4bCHF 18.8b27.2x22x3.4x
Wed, 20 Dec 2023CHF 393.8bCHF 120.0bCHF 18.7b24.8x21x3.3x
Fri, 17 Nov 2023CHF 386.0bCHF 121.7bCHF 19.0b23.7x20.3x3.2x
Sun, 15 Oct 2023CHF 409.9bCHF 121.5bCHF 18.6b26.2x22x3.4x
Tue, 12 Sep 2023CHF 399.6bCHF 112.3bCHF 18.0b47.3x22.2x3.6x
Thu, 10 Aug 2023CHF 413.1bCHF 111.6bCHF 17.9b48.1x23.1x3.7x
Sat, 08 Jul 2023CHF 403.5bCHF 114.8bCHF 18.8b35.1x21.4x3.5x
Price to Earnings Ratio

21.4x


Total Market Cap: CHF 403.5bTotal Earnings: CHF 18.8bTotal Revenue: CHF 114.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 22.5x.
  • The 3-year average PS ratio of 3.9x is lower than the industry's current PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 10% per year over the last three years.
  • Revenues for these companies have grown 2.3% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.83%
Healthcare2.93%
Pharma2.66%
Pharma2.66%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ROP Roche HoldingCHF 332.802.3%
+CHF 6.0b		27.7%PE20.6x
NOVN NovartisCHF 126.582.6%
+CHF 5.8b		29.3%PE21.2x
GALD Galderma GroupCHF 183.904.9%
+CHF 2.0b		59.2%PE87.1x
SDZ Sandoz GroupCHF 73.123.7%
+CHF 1.1b		70.3%PE42.8x
NWRN Newron PharmaceuticalsCHF 13.042.7%
+CHF 7.1m		93.5%PS15.4x

Latest News

SDZ
CHF 73.12
Sandoz Group
7D
3.7%
1Y
70.3%
GALD
CHF 183.90
Galderma Group
7D
4.9%
1Y
59.2%
ROP
CHF 332.80
Roche Holding
7D
2.3%
1Y
27.7%
DESN
CHF 276.00
Dottikon ES Holding
7D
-0.7%
1Y
-8.9%
NOVN
CHF 126.58
Novartis
7D
2.6%
1Y
29.3%
Narrative Update • Jun 26

NOVN: Oncology Pipeline Advances Will Drive Future Upside Potential

Analysts have revised their fair value estimate for Novartis to CHF144.47 from CHF138.41, reflecting updated assumptions around revenue growth, the discount rate, and future P/E. What’s in the News for Novartis Novartis agreed to a collaboration with Antares Therapeutics worth up to US$1.9b, including a US$105m upfront payment and potential US$1.8b in milestones, to discover and develop small molecule oncology therapies targeting historically undruggable cancers.
COPN
CHF 66.50
Cosmo
7D
-1.9%
1Y
13.3%
Narrative Update • Jun 22

COPN: European Dermatology Expansion Will Support CHF 160 Upside Potential

Analysts lifted their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple as key drivers of the change. What’s in the News for Cosmo Cosmo Pharmaceuticals N.V. reported that partners Glenmark Specialty S.A. and InfectoPharm launched Winlevi (clascoterone 1% cream) in key European markets, including Austria and Germany, following European Commission marketing authorization, according to recent company news.
CURN
CHF 22.20
Curatis Holding
7D
-4.7%
1Y
104.6%
ADXN
CHF 0.04
Addex Therapeutics
7D
-11.4%
1Y
-34.8%
NWRN
CHF 13.04
Newron Pharmaceuticals
7D
2.7%
1Y
93.5%
New Narrative • May 10

Still A Binary Phase III Bet on Evenamide

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.
BIOV
CHF 26.50
BioVersys
7D
1.9%
1Y
-23.4%